{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received treatment","reportingStatus":"POSTED","timeFrame":"3 weeks","title":"Maximum Serum Concentration","type":"SECONDARY","unitOfMeasure":"microgram/mL"}